OMEZA Holdings licenses its wound-care matrix to Hikma for selected MENA markets

Selected MENA markets only; no African country is named in the release text reviewed, so the African nexus is regional and is flagged accordingly.


Coverage: The Meridian legal market record (editorial).

Selected MENA markets only; no African country is named in the release text reviewed, so the African nexus is regional and is flagged accordingly.

Record ID TX-AFR-2026-0024
Record type Commercial IP transaction
Transaction type Patent licence, Exclusive licence, In-licensing, Trade mark licence
IP rights patent, know-how, trade mark
Status Signed
Qualifying date 2026-09-21
Sector Life sciences · Medical devices and wound care
African markets Multi-jurisdictional
Licensed territory Selected MENA markets; no list in the release.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • OMEZA Holdings Inc. (United States): licensor
  • Hikma Pharmaceuticals (United Kingdom): licensee

Key terms

  • Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: Selected MENA markets

Sources

  1. OMEZA Holdings Announces an Exclusive Licensing Agreement with Hikma in Select MENA Markets, OMEZA Holdings (via PRWeb), 2026-09-21

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.